BIT
CASC

BlackRock Institutional Trust’s Cascadian Therapeutics, Inc. CASC Stock Holding History

BlackRock Institutional Trust’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.33M Sell
308,243
-3
-0% -$19 ﹤0.01% 3200
2016
Q3 		$3.03M Buy
308,246
+3,901
+1% +$27.7K ﹤0.01% 2890
2016
Q2 		$1.72M Sell
304,345
-132,805
-30% -$902K ﹤0.01% 3093
2016
Q1 		$3.33M Sell
437,150
-27,388
-6% -$211K ﹤0.01% 2837
2015
Q4 		$6.19M Sell
464,538
-11,181
-2% -$193K ﹤0.01% 2598
2015
Q3 		$7.82M Sell
475,719
-105,589
-18% -$2.16M ﹤0.01% 2450
2015
Q2 		$13M Buy
581,308
+105
+0% +$1.66K ﹤0.01% 2231
2015
Q1 		$5.68M Buy
581,203
+57,516
+11% +$564K ﹤0.01% 2709
2014
Q4 		$5.97M Buy
523,687
+7,615
+1% +$82.6K ﹤0.01% 2654
2014
Q3 		$5.95M Buy
516,072
+44,934
+10% +$686K ﹤0.01% 2608
2014
Q2 		$9.16M Buy
471,138
+104,697
+29% +$1.85M ﹤0.01% 2489
2014
Q1 		$6.57M Buy
366,441
+48,896
+15% +$803K ﹤0.01% 2666
2013
Q4 		$3.35M Buy
317,545
+77,106
+32% +$862K ﹤0.01% 2953
2013
Q3 		$2.97M Buy
240,439
+31,039
+15% +$327K ﹤0.01% 2951
2013
Q2 		$1.97M Buy
+209,400
New +$2.69M ﹤0.01% 3072

Other funds holding CASC

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BlackRock Institutional Trust's CASC Position: Q4 2016 in Review

BlackRock Institutional Trust reduced its Cascadian Therapeutics, Inc. (CASC) stake by 0% in Q4 2016, selling an estimated $19 and leaving 308,243 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #3200.

BlackRock Institutional Trust first reported a position in CASC in Q2 2013 and has held it in 15 quarters since. The position peaked at $13M in Q2 2015. 57 funds tracked by Wall St. Rank hold CASC as of Q4 2016.

  • BlackRock Institutional Trust held 308,243 shares of Cascadian Therapeutics, Inc. worth $1.33M as of Q4 2016.
  • BlackRock Institutional Trust sold 3 Cascadian Therapeutics, Inc. shares in Q4 2016, an estimated $19.
  • Cascadian Therapeutics, Inc. made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3200 holding.
  • BlackRock Institutional Trust first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Institutional Trust's Cascadian Therapeutics, Inc. position peaked at $13M in Q2 2015.
  • 57 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.